ACXP

Acurx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company focused on developing antibiotics to treat bacterial infections. Headquartered in Staten Island, New York, the company specializes in creating innovative therapies targeting difficult-to-treat pathogens, with particular emphasis on Clostridioides difficile (C. difficile) infections and other gastrointestinal diseases. Acurx's lead product candidate, ibezapolstat, is a novel antibiotic that inhibits bacterial DNA polymerase IIIC (pol IIIC), representing a first-in-class mechanism for treating C. difficile infections. The company's pipeline also includes additional early-stage antibiotic candidates targeting gram-positive bacteria. Acurx maintains strategic collaborations to advance its drug development programs and has conducted multiple clinical trials demonstrating ibezapolstat's potential efficacy and safety profile. The company holds multiple patents and intellectual property protections covering its proprietary antibiotic compounds and their therapeutic applications. In recent developments, Acurx has progressed ibezapolstat through Phase 2 clinical trials and announced plans for advancing toward late-stage development. The company operates with a lean organizational structure typical of clinical-stage biotechnology firms, focusing resources on research and development activities. Acurx went public through a traditional initial public offering and trades on the Nasdaq stock exchange, providing investors access to a pure-play opportunity in the antibiotic development sector.